BR112022019647A2 - Vetores para produção de partículas semelhantes a vírus e usos das mesmas - Google Patents
Vetores para produção de partículas semelhantes a vírus e usos das mesmasInfo
- Publication number
- BR112022019647A2 BR112022019647A2 BR112022019647A BR112022019647A BR112022019647A2 BR 112022019647 A2 BR112022019647 A2 BR 112022019647A2 BR 112022019647 A BR112022019647 A BR 112022019647A BR 112022019647 A BR112022019647 A BR 112022019647A BR 112022019647 A2 BR112022019647 A2 BR 112022019647A2
- Authority
- BR
- Brazil
- Prior art keywords
- vectors
- virus
- particles
- production
- vlps
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003281P | 2020-03-31 | 2020-03-31 | |
| US202063124397P | 2020-12-11 | 2020-12-11 | |
| PCT/IB2021/052710 WO2021198963A1 (en) | 2020-03-31 | 2021-03-31 | Vectors for producing virus-like particles and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019647A2 true BR112022019647A2 (pt) | 2022-11-29 |
Family
ID=77927692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019647A BR112022019647A2 (pt) | 2020-03-31 | 2021-03-31 | Vetores para produção de partículas semelhantes a vírus e usos das mesmas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230140025A1 (https=) |
| EP (1) | EP4127191A4 (https=) |
| JP (1) | JP2023520038A (https=) |
| KR (1) | KR20230034934A (https=) |
| CN (1) | CN115956125A (https=) |
| AU (1) | AU2021249531A1 (https=) |
| BR (1) | BR112022019647A2 (https=) |
| CA (1) | CA3176880A1 (https=) |
| MX (1) | MX2022011734A (https=) |
| WO (1) | WO2021198963A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2431963T3 (es) * | 2002-07-05 | 2013-11-28 | Folia Biotech Inc. | Partícula viral adyuvante |
| US9290778B2 (en) * | 2013-11-22 | 2016-03-22 | Mediphage Bioceuticals, Inc. | DNA vector production system |
| US9862954B2 (en) * | 2012-11-22 | 2018-01-09 | Mediphage Bioceuticals, Inc. | DNA vector production system |
| CA2906770A1 (en) * | 2013-03-15 | 2014-09-18 | Vlp Biotech, Inc. | Palivizumab epitope-based virus-like particles |
| EP3275462A1 (en) * | 2016-07-27 | 2018-01-31 | Fundació Privada Institut de Recerca de la SIDA-Caixa | Virus-like particles with high-density coating for the production of neutralizing antibodies |
| US10960070B2 (en) * | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
-
2021
- 2021-03-31 BR BR112022019647A patent/BR112022019647A2/pt unknown
- 2021-03-31 JP JP2022559858A patent/JP2023520038A/ja active Pending
- 2021-03-31 AU AU2021249531A patent/AU2021249531A1/en not_active Abandoned
- 2021-03-31 WO PCT/IB2021/052710 patent/WO2021198963A1/en not_active Ceased
- 2021-03-31 MX MX2022011734A patent/MX2022011734A/es unknown
- 2021-03-31 KR KR1020227038042A patent/KR20230034934A/ko active Pending
- 2021-03-31 CA CA3176880A patent/CA3176880A1/en active Pending
- 2021-03-31 CN CN202180038779.4A patent/CN115956125A/zh active Pending
- 2021-03-31 EP EP21779933.7A patent/EP4127191A4/en active Pending
-
2022
- 2022-09-30 US US17/937,234 patent/US20230140025A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023520038A (ja) | 2023-05-15 |
| US20230140025A1 (en) | 2023-05-04 |
| EP4127191A4 (en) | 2024-05-15 |
| KR20230034934A (ko) | 2023-03-10 |
| CA3176880A1 (en) | 2021-10-07 |
| WO2021198963A1 (en) | 2021-10-07 |
| MX2022011734A (es) | 2022-12-15 |
| AU2021249531A1 (en) | 2022-10-20 |
| CN115956125A (zh) | 2023-04-11 |
| EP4127191A1 (en) | 2023-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025003310A (es) | Integracion dirigida de acidos nucleicos | |
| MX2021014007A (es) | Proteinas de union a epcam y metodos de uso. | |
| BR112018068391A2 (pt) | sistema e métodos para produzir uma proteína, célula inoculada, construção de rna para expressar a replicase de alfavírus e dna | |
| SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
| BR112018007538A2 (pt) | células exterminadoras naturais e células ilc3 e usos das mesmas | |
| BR112018013808A2 (pt) | dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer | |
| BR112017014269A2 (pt) | células exterminadoras naturais e usos das mesmas | |
| PH12019500626A1 (en) | Aav treatment of huntington's disease | |
| BR112022016550A2 (pt) | Proteínas de ligação a flt3 e métodos de uso | |
| EP4477662A3 (en) | Nucleic acid molecules and uses thereof | |
| CY1123343T1 (el) | Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων | |
| MX395421B (es) | Moleculas de acido nucleico artificiales. | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| MX2016008551A (es) | Moleculas artificiales de acido nucleico. | |
| MX342995B (es) | Métodos de generar células asesinas naturales. | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| BR112016030326A2 (pt) | ?poliepítopo quimérico, polinucleotídeo, vetores, célula, partículas de vírus, composição imunogênica, método para prevenir e/ou tratar infecções e método de produção de partículas de mv? | |
| MX2021006398A (es) | Expansión de células asesinas naturales y células ilc3 con compuestos aromáticos novedosos. | |
| JOP20210186A1 (ar) | مستضدات البروستاتا المستحدثة واستخداماتها | |
| BR112018073238A2 (pt) | vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer | |
| MX395742B (es) | Dnasa modificada y usos de la misma. | |
| BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
| BR112017002166A2 (pt) | terapias antibióticas de peptídeos derivados do búfalo d?água | |
| WO2022026885A3 (en) | Modified chikungunya viruses and sindbis viruses and uses thereof |